Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study

<strong>Background</strong> The recombinant vesicular stomatitis virus (rVSV) vaccine expressing the Zaire Ebola virus (ZEBOV) glycoprotein is efficacious in the weeks following single-dose injection, but duration of immunity is unknown. We aimed to assess antibody persistence at 1 and 2...

Full description

Bibliographic Details
Main Authors:	Huttner, A, Agnandji, S, Combescure, C, Fernandes, J, Bache, E, Kabwende, L, Ndungu, F, Brosnahan, J, Monath, T, Lemaître, B, Grillet, S, Botto, M, Engler, O, Portmann, J, Siegrist, D, Bejon, P, Silvera, P, Kremsner, P, Siegrist, C, Krishna, S, Addo, M, Becker, S, Krähling, V, Njuguna, P, Kieny, M, Ahmed, R, Anderson, J, Auderset, F, Borgianni, L, Ciabattini, A, Haks, M, Harandi, A, Heppner, D, Gerlini, A, Medaglini, D, Ottenhoff, T, Pejoski, D, Page, M, Pozzi, G, Santoro, F, Dubey, S, Nakaya, H, Orourke, F, Rothenberger, S
Format:	Journal article
Published:	Elsevier 2018

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study

Similar Items